NDT Pharmaceuticals (NDT Pharmaceuticals) EV-to-EBIT : -96.78 (As of Jun. 22, 2024)

NDT Pharmaceuticals EV-to-EBIT Chart

NDT Pharmaceuticals Quarterly Data
	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08
EV-to-EBIT	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of NDT Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, NDT Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NDT Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NDT Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NDT Pharmaceuticals's EV-to-EBIT falls into.

NDT Pharmaceuticals EV-to-EBIT Calculation

NDT Pharmaceuticals's EV-to-EBIT for today is calculated as:

NDT Pharmaceuticals's current Enterprise Value is $24.00 Mil.
NDT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NDT Pharmaceuticals  (OTCPK:NDTP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NDT Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2008 is calculated as:

NDT Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2008 was $42.93 Mil.
NDT Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2008 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NDT Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NDT Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NDT Pharmaceuticals (NDT Pharmaceuticals) Business Description